RxDoctor Payments Data

Ashley Stines

Family · Tuscaloosa, ALNPI 1497373328

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 87.7% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $14,071, more than ten times the $115 reported in 2021. Among family clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,090in general payments, 2019–2025

Across 238 payments — averaging $122.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$26K
  • Viiv Healthcare Company$2K
  • Johnson & Johnson$263
  • Janssen Products, LP$222
  • Merck$169
  • AbbVie$126
  • plus $385 from 9 others

What the payments were for

  • Consulting fees$1,5705%
  • Speaking & faculty fees$14,24549%
  • Travel & lodging$6,61023%
  • Food & beverage$6,53822%
  • Education$1270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,090 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala309$1,202,808
DescovyEmtricitabine/Tenofov Alafenam131$292,698
OdefseyEmtricitab/Rilpiviri/Tenof Ala77$275,198
GenvoyaElviteg/Cob/Emtri/Tenof Alafen60$243,586
JulucaDolutegravir/Rilpivirine70$243,208
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf51$235,582
DovatoDolutegravir Sodium/Lamivudine51$147,868
TivicayDolutegravir Sodium58$126,943
PrezcobixDarunavir/Cobicistat22$51,264
Darunavir50$49,314
MounjaroTirzepatide26$34,555
IsentressRaltegravir Potassium16$31,481
TrulicityDulaglutide13$31,417
JanuviaSitagliptin Phosphate35$24,582
EliquisApixaban13$13,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$25,526$1,739,093500 claims
Viiv Healthcare CompanyJuluca, Dovato, Tivicay$2,400$518,019179 claims
Janssen Products, LPSymtuza$222$235,58251 claims
Lilly USA, LLCMounjaro, Trulicity$101$65,97239 claims
MerckIsentress, Januvia$169$56,06351 claims
Johnson & JohnsonPrezcobix$263$51,26422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →